Explore
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
0 Ungluers have
Faved this Work
Login to Fave
Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 42 times via unglue.it ebook links.
- 42 - pdf (CC BY) at Unglue.it.
Keywords
- 5-FU resistance
- 8-hydroxydaidzein
- affibody drug conjugate (AffiDC)
- affibody molecule
- albumin binding domain
- Angiogenesis
- anti-cancer agent
- anticancer drug
- Apoptosis
- AQ4N
- Autophagy
- B-lactam steroid alkylators
- BCR-ABL
- biomarker
- bioprecursor
- Breast cancer
- BxPC-3
- c-myc
- cancer hallmarks
- CCN1
- colorectal cancer
- Connectivity Map
- CYP1A1
- CYP1B1
- CYP2W1
- Cytochrome P450
- DM1
- drug repurposing
- duocarmycin
- EGFR tyrosine kinase inhibitor
- emtansine
- Expression
- Gene silencing
- Genomics of Drug Sensitivity in Cancer
- Glioblastoma
- HepG2
- History of engineering & technology
- Huh7
- human epidermal growth factor receptor 3 (HER3)
- hybrid steroidal alkylating agents
- in vivo imaging
- Invasion
- isatin sulfonamides
- K562
- MAPK
- mesenchymal–amoeboid transition
- microtubule acetylation
- migration
- molecular docking
- n/a
- Nanoparticles
- nanosystems
- NF-κB
- oncogene
- ovarian cancer
- phortress
- photon upconversion
- PLGA
- poly (ADP-ribose) polymerase inhibitors
- prodrug
- RNA interference
- siRNA
- synthetic lethality
- Technology, engineering, agriculture
- Technology: general issues
- triple-negative breast cancer
- triplet-triplet annihilation
Links
DOI: 10.3390/books978-3-0365-5222-4Editions